Did You Know...
...that the video game, Pong, was invented by a guy who graduated at the bottom of his engineering class? Nolan Bushnell spent more time running the games at a local amusement park than he did on his studies at the University of Utah. His dreams of working for Disney's amusement empire were dashed when the company wouldn't hire him. Taking a boring job, Nolan daydreamed about electronic versions of popular games. He invented Pong, the first video game, and went on to found Atari Co.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 7981398 | PEGylation by the dock and lock (DNL) technique The present invention concerns methods and compositions for forming PEGylated complexes of defined stoichiometry and structure. In preferred embodiments, the PEGylated complex is formed using dock-and-lock technology, by attaching a target agent to a DDD sequence an... | 07/19/2011 |
| 7858070 | Multivalent immunoglobulin-based bioactive assemblies The present invention concerns methods and compositions for stably tethered structures of defined compositions, which may have multiple functionalities and/or binding specificities. Preferred embodiments concern hexameric stably tethered structures comprising one or... | 12/28/2010 |
| 7541018 | Treatment process using somatostatin analogues In one embodiment, a method for treating a cancerous disease is provided which includes characterizing a disease by an overexpression of one or more somatostatin receptors, and exposing the one or more somatostatin receptors to a pharmaceutical composition comprisin... | 06/02/2009 |
| 7374765 | Methods and compositions for diagnosis and treatment of iron misregulation diseases Methods and compositions are provided for the diagnosis and treatment of iron misregulation diseases, including HFE polypeptides, agonists, and antagonists, and transferrin receptor agonists and antagonists. ... | 05/20/2008 |
| 7344699 | Drug conjugate comprising an erythropoietin receptor ligand and an anticancer agent A drug conjugate comprising a targeting agent and an anti-cancer agent, wherein said targeting agent comprises an erythropoietin receptor ligand, is described. The drug conjugate can be used in methods of treating cancer. Also described are methods of treating cance... | 03/18/2008 |
| 7335491 | Production of anti-abeta An improved system for large scale production of proteins and/or polypeptides in cell culture, particularly in media characterized by one or more of: i) a cumulative amino acid concentration greater than about 70 mM; ii) a molar cumulative glutamine to cumulative as... | 02/26/2008 |
| 7332294 | CXCL10-based diagnosis and treatment of respiratory illnesses Elevated blood levels of the chemokine CXCL10 polypeptide are associated with respiratory illnesses (e.g. SARS, influenza and community-acquired pneumonia) and are useful in diagnosis of patients. Methods are provided for diagnosis and treatment of patients sufferin... | 02/19/2008 |
| 7329405 | Human antibodies specific for interleukin 15 (IL-15) Isolated human monoclonal antibodies which specifically bind to IL-15 (e.g., human IL-15), and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced in a transfectoma or in a non-human transgenic animal, e.g., a trans... | 02/12/2008 |
| 7320790 | Humanized antibodies Humanized forms of mouse antibody 10D5 that retain the binding properties of mouse 10D5 are disclosed. Also disclosed are processes for making the humanized antibody, intermediates for making the humanized antibodies, including, nucleotide sequences, vectors, transf... | 01/22/2008 |
| 7318923 | Humanized anti-βantibodies Humanized forms of mouse antibody 3D6 that retain the binding properties of mouse 3D6 are disclosed. Also disclosed are processes for making the humanized antibody, intermediates for making the humanized antibodies, including, nucleotide sequences, vectors, transfor... | 01/15/2008 |
| 7300773 | Production of TNFR-Ig An improved system for large scale production of proteins and/or polypeptides in cell culture, particularly in media characterized by one or more of: i) a cumulative amino acid concentration greater than about 70 mM; ii) a molar cumulative glutamine to cumulative as... | 11/27/2007 |
| 7294484 | Production of polypeptides An improved system for large scale production of proteins and/or polypeptides in cell culture, particularly in media characterized by one or more of: i) a cumulative amino acid concentration greater than about 70 mM; ii) a molar cumulative glutamine to cumulative as... | 11/13/2007 |
| 7285620 | Human chemotactic cytokine The invention relates to isolated and/or recombinant nucleic acids which encode a human chemotactic cytokine designated human eotaxin, and to isolated and/or recombinant human eotaxin proteins or polypeptides, including synthetic polypeptides. The invention further ... | 10/23/2007 |
| 7276364 | Nucleic acids encoding endotheliases, endotheliases and uses thereof Provided herein are endotheliases and portions, particularly, the protease domains, and nucleic acids that encode the endotheliases. The endotheliases are transmembrane proteases expressed in endothelial cells. The nucleic acids and encoded proteins and protease dom... | 10/02/2007 |
| 7265201 | Human chemotactic cytokine The present invention relates to isolated and/or recombinant nucleic acids which encode a human chemotactic cytokine designated human eotaxin, and to proteins or polypeptides referred to herein as isolated and/or recombinant human eotaxin, including synthetic polype... | 09/04/2007 |
| 7261875 | Dendritic poly (amino acid) carriers and methods of use The present invention concerns a design for dendritic poly(amino acid) polymer carriers, also known as nonlinear polymers, and their applications. These dendritic poly(amino acid) carriers have multiple functional groups at the polymer surface. In addition, they hav... | 08/28/2007 |
| 7247304 | Methods of treating using anti-IL-15 antibodies Isolated human monoclonal antibodies which specifically bind to IL-15 (e.g., human IL-15), and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced in a transfectoma or in a non-human transgenic animal, e.g., a trans... | 07/24/2007 |
| 7238711 | Compounds and methods to inhibit or augment an inflammatory response Isolated and purified chemokine peptides, variants, and derivatives thereof, as well as chemokine peptide analogs, are provided. ... | 07/03/2007 |
| 7235358 | Methods and compositions for diagnosing and monitoring transplant rejection Methods of diagnosing or monitoring transplant rejection, particularly cardiac transplant rejection, in a patient by detecting the expression level of one or more genes in a patient, are described. Diagnostic oligonucleotides for diagnosing or monitoring transplant ... | 06/26/2007 |
| 7229604 | Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging The invention provides, in a general sense, a new labeling strategy employing 99mTc chelated with ethylenedicysteine (EC). EC is conjugated with a variety of ligands and chelated to 99mTc for use as an imaging agent for tissue-specific diseases... | 06/12/2007 |
| 7223380 | Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging The invention provides, in a general sense, a new labeling strategy employing 99mTc chelated with ethylenedicysteine (EC). EC is conjugated with a variety of ligands and chelated to 99mTc for use as an imaging agent for tissue-specific diseases... | 05/29/2007 |
| 7214658 | Method of delivering a TNF antagonist to the brain of a human by perispinal administration without direct intrathecal injection The present invention provides specific methods of using and administering etanercept to improve cognitive function in a human, for both the treatment and prevention of cognitive impairment, or, alternatively, to enhance cognitive function including Alzheimer's Dise... | 05/08/2007 |
| 7192570 | Compositions of somatostatin analogues In one embodiment, a composition of somatostatin analogues having the general formula: is provided wherein Z may be absent or present and when present is selected from DOTA- and DTPA-based chelators, NOTA-based c... | 03/20/2007 |
| 7192736 | Nucleic acid molecules encoding cytotoxic conjugates that contain a chemokine receptor targeting agent Nucleic acid moleucles that encode conjugates containing as a ligand a chemokine receptor targeting agent, such as a chemokine, and a targeted agent, such as a toxin are provided. These conjugates are used to treat inflammatory responses associated with activation, ... | 03/20/2007 |
| 7183377 | Human FRP and fragments thereof including methods for using them The invention provides a novel, secreted protein that contains a region homologous to ligand binding domain of a cytokine receptor. This protein, called Frizzled-related protein (FRP), antagonizes the signaling of the Wnt family of cytokines. Extracellular signaling... | 02/27/2007 |
| 7172892 | Nucleic acid molecules encoding serine protease CVSP14, the encoded polypeptides and methods based thereon Provided herein are polypeptides designated CVSP14 polypeptides that exhibit protease activity as a single chain or as an activated two chain form. Methods using the polypeptides to identify compounds that modulate the protease activity thereof are provided. The pol... | 02/06/2007 |
| 7166702 | Cytotoxic conjugates comprising a chemokine receptor targeting agent Conjugates containing as a ligand chemokine receptor targeting agents, such as chemokines, and a targeted agent, such as a toxin are provided. These conjugates are used to treat inflammatory responses associated with activation, proliferation and migration of immune... | 01/23/2007 |
| 7163671 | Long-term stabilized formulations A stable protein formulation containing tryptophan or a tryptophan derivative or a salt thereof as a stabilizer. ... | 01/16/2007 |
| 7157418 | Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders Conjugates containing as a ligand a chemokine receptor targeting agents, such as chemokines, and a targeted agent, such as a toxin are provided. These conjugates are used to treat inflammatory responses associated with activation, proliferation and migration of immu... | 01/02/2007 |
| 7153507 | Human antibodies specific for interleukin 15 (IL-15) Isolated human monoclonal antibodies which specifically bind to IL-15 (e.g., human IL-15), and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced in a transfectoma or in a non-human transgenic animal, e.g., a trans... | 12/26/2006 |
| 7141651 | Multiple cytokine protein complexes The invention relates to protein complexes and fusion proteins including at least two different cytokine molecules. The protein complexes and fusion proteins may further include a targeting moiety such as a region of an immunoglobulin. Methods of using the protein c... | 11/28/2006 |
| 7125703 | Nucleic acid molecules encoding a transmembrane serine protease 7, the encoded polypeptides and methods based thereon Provided herein are type II transmembrane serine protease 7 (MTSP7) polypeptides. Zymogen and activated forms of these polypeptides as well as single and two chain forms of the protease domain are also provided. Methods using the polypeptides to identify compounds t... | 10/24/2006 |
| 7112430 | Nucleic acid molecules encoding a transmembrane serine protease 10, the encoded polypeptides and methods based thereon Provided herein are type II transmembrane serine protease 10 (MTSP10) polypeptides. Zymogen and activated forms of these polypeptides as well as single and two chain forms of the protease domain are also provided. Methods using the polypeptides to identify compounds... | 09/26/2006 |
| 7105333 | Nucleic acid molecules encoding a transmembrane serine protease 9, the encoded polypeptides and methods based thereon Provided herein are type II transmembrane serine protease 9 (MTSP9) polypeptides. Zymogen and activated forms of these polypeptides as well as single and two chain forms of the protease domain are also provided. Methods using the polypeptides to identify compounds t... | 09/12/2006 |
| 7101542 | Cell-mediated targeting of toxins to pathogenic cells The invention features vectors encoding immunotoxic fusion proteins containing targeting domains and toxic domains, targeting cells transduced with the vectors, methods of making the targeting cells, and methods of treating diseases (e.g., cancer) using both the vec... | 09/05/2006 |
| 7083983 | Inhibitors of the interaction between P53 and MDM2 The present invention relates to compounds capable of binding to the oncogene protein MDM2, processes for the preparation of such compounds, pharmaceutical preparations comprising such compounds, and uses of said compounds, e.g. in the therapeutic (including prophyl... | 08/01/2006 |
| 7078013 | Pretargeting methods and compounds Methods, compounds, compositions and kits that relate to pretargeted delivery of diagnostic and therapeutic agents are disclosed. In particular, methods for radiometal labeling of biotin and for improved radiohalogenation of biotin, as well as related compounds, are... | 07/18/2006 |
| 7067117 | Compounds and methods to inhibit or augment an inflammatory response Isolated and purified chemokine peptides, variants, and derivatives thereof, as well as chemokine peptide analogs, are provided. ... | 06/27/2006 |
| 7067111 | Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging The invention provides, in a general sense, a new labeling strategy employing 99mTc chelated with ethylenedicysteine (EC). EC is conjugated with a variety of ligands and chelated to 99mTc for use as an imaging agent for tissue-specific diseases... | 06/27/2006 |
| 7060689 | Methods and compositions for delivery and retention of active agents to lymph nodes The present invention is directed to delivery and retention of active agents to targeted lymph nodes in a mammal using a ligand/anti-ligand pair. More particularly, the invention involves methods, compositions, and kits for delivery and retention of active agents to... | 06/13/2006 |
